SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME
Clinical trials for SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME trials appear
Sign up with your email to follow new studies for SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising seizure drug study halted early
Disease control TerminatedThis study looked at the long-term safety of the drug NBI-921352 for people with a rare genetic seizure disorder called SCN8A-DEE. It was an extension of an earlier study, and participants took the drug alongside their usual seizure medications. The study was stopped early and on…
Matched conditions: SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Promising epilepsy drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare, severe form of epilepsy caused by a change in the SCN8A gene. The goal was to see if adding this drug to their current seizure medicines could reduce how often they had seizures. The tria…
Matched conditions: SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME
Phase: PHASE2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC